Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Production of Pharmaceuticals

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Public biotech in 2022 - the numbers.

Nature biotechnology·2023

Same author

Public biotech in 2021 - the numbers.

Nature biotechnology·2022

Same author

Public biotech 2018-the numbers.

Nature biotechnology·2019

Same author

Public biotech in 2017-the numbers.

Nature biotechnology·2018

Same author

Public biotech in 2016-the numbers.

Nature biotechnology·2017

Same author

Biotech's wellspring-a survey of the health of the private sector in 2016.

Nature biotechnology·2017

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Public biotech 2007--the numbers.

Stacy Lawrence, Riku Lähteenmäki

Nature Biotechnology

|July 10, 2008

Summary

This summary is machine-generated.

Record profits in the public biotechnology sector are likely unsustainable due to economic downturns. Future financing may be challenging for biotech companies.

More Related Videos

Real-time Cytotoxicity Assays in Human Whole Blood

Real-time Cytotoxicity Assays in Human Whole Blood

Published on: November 7, 2014

Optimization and Utilization of Agrobacterium-mediated Transient Protein Production in Nicotiana

Optimization and Utilization of Agrobacterium-mediated Transient Protein Production in Nicotiana

Published on: April 19, 2014

Related Experiment Videos

Last Updated: Jul 3, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Real-time Cytotoxicity Assays in Human Whole Blood

Real-time Cytotoxicity Assays in Human Whole Blood

Published on: November 7, 2014

Optimization and Utilization of Agrobacterium-mediated Transient Protein Production in Nicotiana

Optimization and Utilization of Agrobacterium-mediated Transient Protein Production in Nicotiana

Published on: April 19, 2014

Area of Science:

Biotechnology
Economics
Finance

Background:

The public biotechnology sector has experienced record profits and significant financing rounds.
Current economic conditions present potential challenges to sustained growth.

Purpose of the Study:

To analyze the sustainability of current financial trends in the public biotech sector.
To forecast potential impacts of economic downturns on biotech financing.

Main Methods:

Analysis of financial data from public biotechnology companies.
Economic forecasting models applied to the biotech industry.

Main Results:

Record profits and financing levels may not be sustainable in the near future.
Economic instability poses a significant risk to the biotechnology sector's financial health.

Conclusions:

The biotechnology sector should prepare for potential reductions in profits and financing.
Economic headwinds may necessitate strategic financial planning for biotech firms.